Literature DB >> 16262645

Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine.

Helen E Grote1, Natalie D Bull, Monique L Howard, Anton van Dellen, Colin Blakemore, Perry F Bartlett, Anthony J Hannan.   

Abstract

Huntington's disease (HD) is a neurodegenerative disorder caused by an expanded CAG trinucleotide repeat encoding an extended polyglutamine tract in the huntingtin protein. Affected individuals display progressive motor, cognitive and psychiatric symptoms (including depression), leading to terminal decline. Given that transgenic HD mice have decreased hippocampal cell proliferation and that a deficit in neurogenesis has been postulated as an underlying cause of depression, we hypothesized that decreased hippocampal neurogenesis contributes to depressive symptoms and cognitive decline in HD. Fluoxetine, a serotonin-reuptake inhibitor commonly prescribed for the treatment of depression, is known to increase neurogenesis in the dentate gyrus of wild-type mouse hippocampus. Here we show that hippocampal-dependent cognitive and depressive-like behavioural symptoms occur in HD mice, and that the administration of fluoxetine produces a marked improvement in these deficits. Furthermore, fluoxetine was found to rescue deficits of neurogenesis and volume loss in the dentate gyrus of HD mice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16262645     DOI: 10.1111/j.1460-9568.2005.04365.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  46 in total

Review 1.  Neurogenesis and exercise: past and future directions.

Authors:  Henriette van Praag
Journal:  Neuromolecular Med       Date:  2008-02-20       Impact factor: 3.843

2.  Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.

Authors:  Wenzhen Duan; Qi Peng; Naoki Masuda; Eric Ford; Erik Tryggestad; Bruce Ladenheim; Ming Zhao; Jean Lud Cadet; John Wong; Christopher A Ross
Journal:  Neurobiol Dis       Date:  2008-03-10       Impact factor: 5.996

Review 3.  Huntington's disease: can mice lead the way to treatment?

Authors:  Zachary R Crook; David Housman
Journal:  Neuron       Date:  2011-02-10       Impact factor: 17.173

4.  Treatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise.

Authors:  Thibault Renoir; Terence Y C Pang; Michelle S Zajac; Grace Chan; Xin Du; Leah Leang; Caroline Chevarin; Laurence Lanfumey; Anthony J Hannan
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 5.  Huntington's disease: the coming of age.

Authors:  Mritunjay Pandey; Usha Rajamma
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

6.  Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model.

Authors:  Zacharias Kohl; Beate Winner; Kiren Ubhi; Edward Rockenstein; Michael Mante; Martina Münch; Carolee Barlow; Todd Carter; Eliezer Masliah; Jürgen Winkler
Journal:  Eur J Neurosci       Date:  2012-01       Impact factor: 3.386

7.  Prevalence of incompletely penetrant Huntington's disease alleles among individuals with major depressive disorder.

Authors:  Roy H Perlis; Jordan W Smoller; Jayalakshmi Mysore; Mei Sun; Tammy Gillis; Shaun Purcell; Marcella Rietschel; Markus M Nöthen; Stephanie Witt; Wolfgang Maier; Dan V Iosifescu; Patrick Sullivan; A John Rush; Maurizio Fava; Hans Breiter; Marcy Macdonald; James Gusella
Journal:  Am J Psychiatry       Date:  2010-04-01       Impact factor: 18.112

8.  Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: reversal by fluoxetine.

Authors:  Katsuaki Suzuki; Kyoko Okada; Tomoyasu Wakuda; Chie Shinmura; Yosuke Kameno; Keiko Iwata; Taro Takahashi; Shiro Suda; Hideo Matsuzaki; Yasuhide Iwata; Kenji Hashimoto; Norio Mori
Journal:  PLoS One       Date:  2010-02-17       Impact factor: 3.240

9.  Impaired adult olfactory bulb neurogenesis in the R6/2 mouse model of Huntington's disease.

Authors:  Zacharias Kohl; Martin Regensburger; Robert Aigner; Mahesh Kandasamy; Beate Winner; Ludwig Aigner; Jürgen Winkler
Journal:  BMC Neurosci       Date:  2010-09-13       Impact factor: 3.288

10.  Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease.

Authors:  Mali Jiang; Qi Peng; Xia Liu; Jing Jin; Zhipeng Hou; Jiangyang Zhang; Susumu Mori; Christopher A Ross; Keqiang Ye; Wenzhen Duan
Journal:  Hum Mol Genet       Date:  2013-02-27       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.